menu
    • menu
    [{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BG-68501","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I","graph3":"Ensem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ensem Therapeutics \/ Ensem Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Ensem Therapeutics \/ Ensem Therapeutics"},{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"ETX-197","moa":"CDK2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ensem Therapeutics","amount2":1.3300000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":1.3300000000000001,"dosageForm":"Undisclosed","sponsorNew":"Ensem Therapeutics \/ BeiGene","highestDevelopmentStatusID":"5","companyTruncated":"Ensem Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ETX-636","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ensem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ensem Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ensem Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ETX\u2013636","moa":"PI3K-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ensem Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ensem Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Ensem Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"GGV Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ensem Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Ensem Therapeutics \/ GGV Capital","highestDevelopmentStatusID":"2","companyTruncated":"Ensem Therapeutics \/ GGV Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Ensem Therapeutics

    Menu

    Ensem Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ensem Therapeutics

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Ensem Therapeutics

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETX-636

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1/2 Study of ETX-636 in Participants with Advanced Solid Tumors

                            Details : ETX-636 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 29, 2025

                            Lead Product(s) : ETX-636

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ensem Therapeutics

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Ensem Therapeutics

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETX–636

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ensem Wins FDA IND Clearance to Start Trials for ETX-636

                            Details : ETX-636 is a potential best-in-class novel allosteric pan-mutant-selective PI3Kα inhibitor and degrader, which is being evaluated for the treatment of advanced solid tumors harboring a PI3Kα mutation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 22, 2025

                            Lead Product(s) : ETX–636

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ensem Therapeutics

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Ensem Therapeutics

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BG-68501,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : BeOne Medicines

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ensem Therapeutics: Milestone Achieved with CDK2 Inhibitor for Solid Tumors

                            Details : BG-68501, a small molecule cyclin-dependent kinase 2 (CDK2) inhibitor, which is being evaluated for the treatment of HR+/HER2 solid tumors including breast, ovarian, and Small Cell Lung Cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 12, 2024

                            Lead Product(s) : BG-68501,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : BeOne Medicines

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ensem Therapeutics

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Ensem Therapeutics

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETX-197

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : BeOne Medicines

                            Deal Size : $1,330.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor

                            Details : Under the agreement, BeiGene will acquire an exclusive global license to an Investigational New Drug application-ready, ETX-197, an oral cyclin-dependent kinase 2 (CDK2) inhibitor.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 21, 2023

                            Lead Product(s) : ETX-197

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : BeOne Medicines

                            Deal Size : $1,330.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ensem Therapeutics

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Ensem Therapeutics

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : GGV Capital

                            Deal Size : $67.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            ENSEM Therapeutics, a CBC Group-Incubated Biopharma Company, Raises $67 Million in Series A Financing to Devel...

                            Details : Proceeds will be used to further advance the company's Kinetic Ensemble platform and accelerate R&D pipeline. Biomolecules such as proteins and RNAs are in constant motion, with an ensemble of conformations that govern their functions.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 06, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : GGV Capital

                            Deal Size : $67.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth